CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: Three cases

Cancer Immunology, Immunotherapy

Volumn 60, Issue 8, 2011, Pages 1137-1146

  Yuan, Jianda ^a   Ginsberg, Brian ^a   Page, David ^a   Li, Yanyun ^a   Rasalan, Teresa ^a   Gallardo, Humilidad F ^a   Xu, Yinyan ^a   Adams, Sylvia ^b   Bhardwaj, Nina ^b   Busam, Klaus ^a   Old, Lloyd J ^a   Allison, James P ^a   Jungbluth, Achim ^a   Wolchok, Jedd D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cytotoxic T lymphocyte antigen 4; Ipilimumab; Melanoma; PIVAC 10; T cell response; Vaccines

Indexed keywords

CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; INTEGRIN ANTIBODY; INTERLEUKIN 2; IPILIMUMAB; ISOLEUCYLTHREONYLASPARTYLGLUTAMINYLVALYLPROPYLPHENYLALANYLSERYLVALINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOPHENOL MONOOXYGENASE; NY ESO 1 ANTIGEN; PEPTIDE VACCINE; PROTEIN ANTIBODY; SORAFENIB; TEMOZOLOMIDE; TYROSYLMETHIONYLASPARTYLGLYCYLTHREONYLMETHIONYLSERYLGLUTAMINYLVALINE; UNCLASSIFIED DRUG; VINBLASTINE;

ADULT; AGED; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; CANCER IMMUNIZATION; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; LOW DRUG DOSE; LYMPH NODE DISSECTION; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SENTINEL LYMPH NODE BIOPSY; SKIN SURGERY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PEPTIDE FRAGMENTS; SKIN NEOPLASMS; TUMOR ESCAPE;

EID: 79960895501     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1011-9     Document Type: Review

References (44)

1. A Jemal R Siegel E Ward, et al. 2008 Cancer statistics, 2008 CA Cancer J Clin 58 71 96 18287387 10.3322/CA.2007.0010 (Pubitemid 351521864)
2. MB Atkins MT Lotze JP Dutcher, et al. 1999 High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 2105 2116 10561265 1:CAS:528:DyaK1MXkvVSmur4%3D (Pubitemid 29318842)
3. TK Eigentler UM Caroli P Radny C Garbe 2003 Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials Lancet Oncol 4 748 759 14662431 10.1016/S1470-2045(03)01280-4 1:CAS:528:DC%2BD3sXps1OgsLo%3D (Pubitemid 37527210)
4. PB Chapman LH Einhorn ML Meyers, et al. 1999 Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma J Clin Oncol 17 2745 2751 10561349 1:CAS:528: DyaK1MXmtlWru70%3D (Pubitemid 29415231)
5. T Petrella I Quirt S Verma, et al. 2007 Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review Cancer Treat Rev 33 484 496 17562357 10.1016/j.ctrv.2007.04.003 1:CAS:528:DC%2BD2sXpvF2ls74%3D (Pubitemid 47333669)
6. + T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival Int J Cancer 126 909 918 19728336 1:CAS:528:DC%2BD1MXhs1SqsLjM
7. JD Wolchok J Yuan AN Houghton, et al. 2007 Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma Mol Ther 15 2044 2050 17726460 10.1038/sj.mt.6300290 1:CAS:528:DC%2BD2sXhtFygsbfL (Pubitemid 350011745)
8. MA Perales J Yuan S Powel, et al. 2008 Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma Mol Ther 16 2022 2029 18797450 10.1038/mt.2008.196 1:CAS:528:DC%2BD1cXhsVSjsbnK
9. DE Spaner I Astsaturov T Vogel, et al. 2006 Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100 Cancer 106 890 899 16404742 10.1002/cncr.21669 1:CAS:528:DC%2BD28XitVCrtb8%3D (Pubitemid 43238457)
10. CL Smith PR Dunbar F Mirza, et al. 2005 Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence Int J Cancer 113 259 266 15386406 10.1002/ijc.20569 1:CAS:528:DC%2BD2cXhtFajtLbL (Pubitemid 39628316)
11. MG Lacelle SM Jensen BA Fox 2009 Partial CD4 depletion reduces regulatory T-cells induced by multiple vaccinations and restores therapeutic efficacy Clin Cancer Res 15 6881 6890 19903784 10.1158/1078-0432.CCR-09-1113 1:CAS:528:DC%2BD1MXhtl2ktL3F
12. T Nicholaou LM Ebert ID Davis, et al. 2009 Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma Clin Cancer Res 15 2166 2173 19276262 10.1158/1078-0432.CCR-08-2484 1:CAS:528:DC%2BD1MXjtF2ru70%3D
13. MF Krummel JP Allison 1995 CD28 and CTLA-4 have opposing effects on the response of T-cells to stimulation J Exp Med 182 459 465 7543139 10.1084/jem.182.2.459 1:CAS:528:DyaK2MXntFKhsL4%3D
14. + immunoregulatory T-cells that control autoimmune diabetes Immunity 12 431 440 10795741 10.1016/S1074-7613(00)80195-8 1:CAS:528:DC%2BD3cXivFyrsbg%3D
15. NJ Karandikar CL Vanderlugt TL Walunas, et al. 1996 CTLA-4: a negative regulator of autoimmune disease J Exp Med 184 783 788 8760834 10.1084/jem.184.2.783 1:CAS:528:DyaK28XltVCrtrs%3D (Pubitemid 26324135)
16. MC Brunner CA Chambers FK Chan, et al. 1999 CTLA-4-mediated inhibition of early events of T-cell proliferation J Immunol 162 5813 5820 10229815 1:CAS:528:DyaK1MXjt12lt7c%3D (Pubitemid 29314933)
17. A van Elsas AA Hurwitz JP Allison 1999 Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation J Exp Med 190 355 366 10430624 10.1084/jem.190.3.355 (Pubitemid 29374833)
18. AV Maker P Attia SA Rosenberg 2005 Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade J Immunol 175 7746 7754 16301685 1:CAS:528:DC%2BD2MXht1ent7vP (Pubitemid 41713475)
19. SA Quezada KS Peggs MA Curran JP Allison 2006 CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T-cells J Clin Invest 116 1935 1945 16778987 10.1172/JCI27745 1:CAS:528:DC%2BD28XmvV2lurw%3D (Pubitemid 44033317)
20. SA Quezada KS Peggs TR Simpson, et al. 2008 Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T-cell depletion against established melanoma J Exp Med 205 2125 2138 18725522 10.1084/jem.20080099 1:CAS:528:DC%2BD1cXhtV2is7%2FP
21. FS Hodi MC Mihm RJ Soiffer, et al. 2003 Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proc Natl Acad Sci USA 100 4712 4717 12682289 10.1073/pnas.0830997100 1:CAS:528:DC%2BD3sXjt12nsL4%3D (Pubitemid 36457795)
22. GQ Phan JC Yang RM Sherry, et al. 2003 Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Proc Natl Acad Sci USA 100 8372 8377 12826605 10.1073/pnas.1533209100 1:CAS:528:DC%2BD3sXlsFGnt7c%3D (Pubitemid 36842552)
23. Lynch T, Neal J, Bondarenko I et al (2010) Phase 2 trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). Presented at the 2010 European Society for Clinical Oncology (ESMO) Annual Meeting; October 8-12, 2010, Milan, Italy. Abstract 375PD
24. Slovin SF, Beer TM, Higano CS et al (2009) Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). Presented at the 2009 American Society for Clinical Oncology (ASCO) Meeting; May 29-June 2, 2009, Orlando, FL. Abstract 5138
25. J Yuan S Gnjatic H Li, et al. 2008 CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T-cell responses in metastatic melanoma patients with clinical benefit Proc Natl Acad Sci USA 105 20410 20415 19074257 10.1073/pnas.0810114105 1:CAS:528:DC%2BD1MXhsFWktA%3D%3D
26. O Klein LM Ebert T Nicholaou, et al. 2009 Melan-A-specific cytotoxic T-cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4 Clin Cancer Res 15 2507 2513 19318477 10.1158/1078-0432.CCR-08-2424 1:CAS:528:DC%2BD1MXjvVWksLY%3D
27. FS Hodi SJ O'Day DF McDermott, et al. 2010 Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 711 723 20525992 10.1056/NEJMoa1003466 1:CAS:528:DC%2BC3cXhtVCrtrbN
28. L Fong SS Kwek S O'Brien, et al. 2009 Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF Cancer Res 69 609 615 19147575 10.1158/0008-5472.CAN-08-3529 1:CAS:528:DC%2BD1MXltFShtQ%3D%3D
29. A Ribas B Comin-Anduix B Chmielowski, et al. 2009 Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma Clin Cancer Res 15 6267 6276 19789309 10.1158/1078-0432.CCR-09-1254 1:CAS:528:DC%2BD1MXhtF2lurjE
30. GY Ku J Yuan DB Page, et al. 2010 Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival Cancer 116 1767 1775 20143434 10.1002/cncr.24951 1:CAS:528:DC%2BC3cXkvFOns7g%3D
31. JD Wolchok A Hoos S O'Day, et al. 2009 Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 7412 7420 19934295 10.1158/1078-0432.CCR-09-1624 1:CAS:528:DC%2BD1MXhsFSnu7vN
32. J Yuan GY Ku HF Gallardo, et al. 2009 Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma Cancer Immun 9 5 19496531
33. C Barrow J Browning D MacGregor, et al. 2006 Tumor antigen expression in melanoma varies according to antigen and stage Clin Cancer Res 12 764 771 16467087 10.1158/1078-0432.CCR-05-1544 1:CAS:528:DC%2BD28XhtFeitbc%3D (Pubitemid 43259856)
34. BC Carthon JD Wolchok J Yuan, et al. 2010 Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial Clin Cancer Res 16 2861 2871 20460488 10.1158/1078-0432.CCR-10-0569 1:CAS:528:DC%2BC3cXlvF2hsrY%3D
35. + T lymphocytes J Immunol 178 4112 4119 17371966 1:CAS:528:DC%2BD2sXjt1WltLY%3D (Pubitemid 46492360)
36. + T lymphocytes with cellular maturation J Exp Med 203 2865 2877 17158960 10.1084/jem.20052246 1:CAS:528:DC%2BD2sXjsFaitw%3D%3D (Pubitemid 46026164)
37. + T-cells with reduced apoptotic susceptibility in rhesus macaques that control virus replication after challenge with pathogenic SIVmac239 J Immunol 179 4732 4740 17878372
38. MG Duvall ML Precopio DA Ambrozak, et al. 2008 Polyfunctional T-cell responses are a hallmark of HIV-2 infection Eur J Immunol 38 350 363 18200635 10.1002/eji.200737768 1:CAS:528:DC%2BD1cXisVehs7c%3D
39. + T-cell responses J Exp Med 204 1405 1416 17535971 10.1084/jem.20062363 1:CAS:528:DC%2BD2sXms1aktL8%3D (Pubitemid 46919878)
40. S Adams DW O'Neill D Nonaka, et al. 2008 Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant J Immunol 181 776 784 18566444 1:CAS:528: DC%2BD1cXnsVGiurk%3D
41. Y Lin HF Gallardo GY Ku, et al. 2009 Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses Cytotherapy 11 1 11 10.1080/14653240903136987
42. L Vence AK Palucka JW Fay, et al. 2007 Circulating tumor antigen-specific regulatory T-cells in patients with metastatic melanoma Proc Natl Acad Sci USA 104 20884 20889 18093940 10.1073/pnas.0710557105 1:CAS:528: DC%2BD1cXkt1Gqtw%3D%3D
43. TM Thomson FX Real S Murakami, et al. 1988 Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies J Invest Dermatol 90 459 466 3280698 10.1111/1523-1747.ep12460906 1:STN:280:DyaL1c7ntV2mtg%3D%3D (Pubitemid 18094872)
44. US Nat ional Institutes of Health. www.ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00836407?term=ipilimumab&rank=6; http://www.clinicaltrials.gov/ct2/show/NCT00357461?term=ipilimumab&rank=26; http:/s/www.clinicaltrials.gov/ct2/show/NCT00124670?term=i pilimumab&rank=42